Molecular targeting in Oncology

by Kaufman, Howard L., M.D.; Wadler, Scott; Antman, Karen

• ISBN13: 9781588295774
• ISBN10: 158829577X
• Edition: 1st
• Format: Hardcover
• Copyright: 2008-03-30
• Publisher: Humana Pr Inc

Summary

In Molecular Targeting in Oncology, authors present an overview of the development of targeted therapies for the treatment of cancer with an emphasis on clinical application. The volume covers the complexity of the rapidly developing area of targeted therapies for the treatment of patients with cancer and is structured in a way so readers may begin with chapters that most interest them and work through the rest of the chapters in the order of their choice. The volume is divided into five sections that cover the most important elements of drug development. The first section focuses on approaches using targeted therapies to inhibit cell growth. The second section describes how clinicians are evaluating targeted therapies in specific organ systems. The third section illustrates how various classes of pharmacologic and immunologic agents are developed for individual molecular targets. The fourth section details new drugs that have novel mechanisms of action. The final section looks to the future of targeted therapeutics and includes chapters on appropriate patient selection, use of combination therapy, dealing with tumor cell resistance, and more.

Table of Contents

Introduction	p. vii
Contributors	p. xiii
General Strategies for Molecular Targeting in Oncology
The Cell Cycle: Therapeutic Targeting of Cell Cycle Regulatory Components and Effector Pathways in Cancer	p. 3
mTOR: Properties and Therapeutics	p. 33
Ras/Raf/MEK Inhibitors	p. 55
17-AAG: Targeting the Molecular Chaperone Heat Shock Protein 90	p. 75
The Cancer Epigenome: Can it be Targeted for Therapy?	p. 97
Molecular Targeting for Specific Disease Sites
Molecular Targeting in Upper Gastrointestinal Malignancies	p. 117
Molecular Targeting of Colorectal Cancer: An Idea Whose Time Has Come	p. 133
Molecular Targeting in Hepatocellular Carcinoma	p. 165
Molecularly Targeted Therapy in Pancreatic Cancer	p. 211
Untargeted Use of Targeted Therapy: A Dilemma in Non-Small Cell Lung Cancer	p. 227
Renal Cell Carcinoma: Renal Cell Cancer	p. 241
Targeted Therapies for Prostate Cancer	p. 263
Molecular Targets in Ovarian Cancer and Endometrial Cancer	p. 291
Targeted Therapy For Breast Cancer	p. 309
Melanoma	p. 343
Classes of Drugs for Molecular Targeting in Oncology
Antibody Therapy of Cancer	p. 371
Nucleic Acid Therapies for Cancer Treatment	p. 413
Engineering Oncolytic Measles Viruses for Targeted Cancer Therapy	p. 431
Vaccines as Targeted Cancer Therapy	p. 447
Cytokine-Based Therapy for Cancer	p. 471
Cyclooxygenase-2 as a Target for Cancer Prevention and Treatment	p. 509
Specific Drugs for Molecular Targeting in Oncology
Imatinib Mesylate (Gleevec) and the Emergence of Chemotherapeutic Drug-Resistant Mutations	p. 545
Development of a Targeted Treatment for Cancer: The Example of C225 (Cetuximab)	p. 559
VEGF Inhibition for Cancer Therapy	p. 573
Somatostatin Analogue Therapy	p. 585
Challenges in Molecular Targeting in Oncology
Patient Selection for Rational Development of Novel Anticancer Agents	p. 641
Clinical Trial Design with Targeted Agents	p. 649
How to Define Treatment Success or Failure if Tumors Do Not Shrink: Consequences for Trial Design	p. 657
Molecular Imaging in Oncology	p. 675
Combinations of Molecular-Targeted Therapies: Opportunities and Challenges	p. 693
Preclinical Development of Molecularly Targeted Agents in Oncology	p. 707
Index	p. 723
Table of Contents provided by Ingram. All Rights Reserved.